Bladder-sparing drug combination for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—one that targets cancer cells directly and another that helps your immune system fight the cancer—to try to get rid of the cancer without needing to remove your bladder. If you have muscle-invasive bladder cancer and are unable or unwilling to have bladder removal surgery, this approach might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with bladder cancer that has grown into the muscle layer of the bladder.
- You have decided not to have your bladder removed (either because you're not healthy enough for surgery or you've chosen not to).
- You are either not healthy enough for the standard chemotherapy drug cisplatin, or you have decided not to take it.
- Your kidneys, liver, and blood counts are within acceptable levels.
- You have not had certain cancer treatments in the past 4 weeks, and you have never taken a topoisomerase inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
This trial tests a combination of two drugs—an antibody-drug conjugate (a targeted therapy that delivers cancer-killing medicine directly to cells) and an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo works better than the standard chemoradiotherapy for bladder cancer when you keep your bladder.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests a new drug combination for advanced bladder or urinary tract cancer that has not been treated before. The study compares a standard chemotherapy plus immunotherapy with and without an extra drug that may reduce side effects.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This trial tests a combination of two drugs, disitamab vedotin and ivonescimab, for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy with cisplatin. The goal is to see if this treatment is safe and effective before surgery.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.